The cost-effectiveness of HIV prevention targeting: How much more bang for the buck?

American Journal of Public Health

Volumn 86, Issue 12, 1996, Pages 1709-1712

  Kahn, James G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; POPULATION RISK; PREVALENCE;

COST-BENEFIT ANALYSIS; EPIDEMIOLOGIC METHODS; HIV INFECTIONS; HUMANS; INCIDENCE; MODELS, STATISTICAL; PREVALENCE; UNITED STATES;

EID: 0030459741     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.86.12.1709     Document Type: Article

References (28)

1. Des Jarlais DC, Padian NS, Winkelstein W, Jr. Targeted HIV-prevention programs. N Engl J Med. 1994;331(21):1451-1453.
2. Stryker J, Bayer R. AIDS policy: two divisive issues. JAMA. 1993;270:2436-2437.
3. Rogers DE, Osborn JE. AIDS policy: two divisive issues. JAMA. 1993;270:494-495.
4. Holtgrave DR, Qualls NL, Curran JW, Valdiserri RO, Guinan ME, Parra WC. Effectiveness and efficiency of HIV prevention services: an overview. Public Health Rep. 1995;110(2):134-146.
5. Vermund SH. Decision making for clinical trials and prevention research: commentary on the model of Paltiel and Kaplan. J Acquir Immune Defic Syndr. 1993;6:176-178. Editorial.
6. Siegel JE, Weinstein MC, Fineberg HV. Bleach programs for preventing AIDS among IV drug users: modeling the impact of HIV prevalence. Am J Public Health. 1991;81:1273-1279.
7. Paltiel AD. Timing is of the essence: matching AIDS policy to the epidemic life cycle. In: Kaplan EH, Brandeau ML, eds. Modeling the AIDS Epidemic. New York, NY: Raven Press; 1994:53-72.
8. Kahn J, Washington AE, Showstack JA, et al. Updated Estimates of the Impact and Cost of HIV Prevention in Injection Drug Users. Report prepared for the Centers for Disease Control and Prevention. San Francisco, Calif: Institute for Health Policy Studies, University of California, San Francisco; 1992.
9. HIV Prevention Planning Council. San Francisco HIV Prevention Plan. San Francisco, Calif: Dept of Public Health, AIDS Office;1995.
10. Osmond DH, Page K, Wiley J, et al. HIV Infection in homosexual/bisexual men, ages 18-29: the San Francisco young men's health study. Am J Public Health. 1994;84:1933-1937.
11. Lemp GF, Hirozawa AM, Givertz D, et al. Seroprevalence of HIV and risk behaviors among young homosexual and bisexual men: the San Francisco/Berkeley young men's survey. JAMA. 1994;272:449-454.
12. Zolopa AR, Hahn JA, Gorter R, et al. HIV and tuberculosis infection in San Francisco's homeless adults: prevalence and risk factors in a representative sample. JAMA. 1994;272:455-461.
13. Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within an HIV epidemic: injecting drug users in New York City, 1984 through 1992. JAMA. 1994;271:121-127.
14. Des Jarlais DC, Padian N, Winkelstein W. Targeted versus generalized AIDS prevention programming in the United States. Presented at the American Association for the Advancement of Science meeting; February 1994; San Francisco, Calif.
15. Seroepidemiology and Surveillance Branch AIDS Office. Projections of the AIDS Epidemic in San Francisco: 1994-1997. San Francisco, Calif: Dept of Public Health; 1994.
16. Watters JK, Cheng Y-T, Bluthenthal R, Carlson JR, Lorvick JJ. Drug injectors and HIV-1 infection in the San Francisco Bay Area. Presented at the Eighth International Conference on AIDS; 1992; Amsterdam, the Netherlands. PoC 4700.
17. Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters R, Osmond D. HIV seroconversion in intravenous drug users in San Francisco. AIDS. 1994;8:223-231.
18. California Community Planning Working Group. California HIV Prevention Plan. San Francisco, Calif: Calif Dept Health Services. Office of AIDS; 1995.
19. Seroepidemiology and Surveillance Branch AIDS Office. HIV Seroprevalence Report. San Francisco, Calif: Dept of Public Health; 1993.
20. Centers for Disease Control and Prevention. National HIV Serosurveillance Summary: Results through 1992. Vol 3. Atlanta, Ga: US Public Health Service; 1994.
21. Kahn JG. Are NEPs cost-effective in preventing HIV infection? In: Lurie PG, Reingold AL, eds. The Public Health Impact of Needle Exchange Programs in the United States and Abroad. Report prepared for the Centers for Disease Control and Prevention. School of Public Health, University of California, Berkeley, and Institute for Health Policy Studies, University of California, San Francisco. San Francisco, Calif: Institute for Health Policy Studies, University of California, San Francisco; 1993:chap 18.
22. Holtgrave DR, Kelly JA. HIV infection among high-risk women: the cost-effectiveness of a behavioral intervention. Am J Public Health. In press.
23. Holtgrave DR, Kelly JA. Cost-effectiveness of an HIV/AIDS prevention intervention for gay men. Presented at the International Conference on AIDS; July 8, 1996; Vancouver, BC, Canada. MoD 1847.
24. Choi KH, Coates TJ. Prevention of HIV infections. AIDS. 1994;8:1371-1389.
25. Booth RE, Watters JK. How effective are risk reduction interventions targeting injecting drug users? AIDS. 1994;8:1515-1524.
26. Over M, Piot P. HIV infection and sexually transmitted diseases. In: Jamison DT, et al., ed. Disease Control Priorities in Developing Countries. New York, NY: Oxford University Press; 1993:455-527.
27. Friedman S, Des Jarlais D. HIV among drug injectors: the epidemic and the response. AIDS Care. 1991;3(3):239-250.
28. Des Jarlais DC, Hagan H, Friedman SR, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274:1226-1231.